LM-24C5

LaNova Medicines Limited · Phase 2 active Small molecule

At a glance

Generic name	LM-24C5
Sponsor	LaNova Medicines Limited
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase II Study of LM-24C5 (PHASE2)
A Study of LM-24C5 For Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LM-24C5 CI brief — competitive landscape report
LM-24C5 updates RSS · CI watch RSS
LaNova Medicines Limited portfolio CI